REXAHN PHARMACEUTICALS INC 10-K 12-31-2012

Company

Opus Genetics, Inc.

Filed

March 22, 2013

Period of Report

December 31, 2012

Accession Number

0001140361-13-013730

A 10-K is a company's comprehensive annual report, required by the SEC. It includes audited financial statements, a description of the business, risk factors, and management's discussion of results. Learn more about 10-K filings →